Skip to main content

Table 3 Patients and tumor characteristics according to the intratumoral OCT1 mRNA expression

From: Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment

Characteristics OCT1 (SLC22A1) OCT1 (SLC22A1) P-value
  Low expression High expression
  (< lower quartile) (≥ lower quartile)
n 15 45
Gender    
 male 14 40  
 female 1 5 1.000
(Fisher’s exact test)
Mean age    
 years (standard deviation) 65.022 (7.190) 64.658 (11.667) 0.910
(unpaired t test)
Underlying liver disease    
 alcohol 2 14  
 HBV 3 8  
 HCV 4 8  
 steatosis or NASH 0 5  
 others 5 6  
 unknown 1 4 0.224
(Fisher’s exact test)
Prior HCC treatment    
 yes 6 29  
 no 9 16 0.133
(Fisher’s exact test)
Tumor grading    
 G1 3 10  
 G2 8 26  
 G3 4 4  
 unknown 0 5 0.265
(Mann–Whitney U test)
Tumor burden    
MVI          absent 4 27  
          present 11 18 0.037
(Fisher’s exact test)
EHS         absent 5 12  
          present 10 33 0.743
(Fisher’s exact test)
MVI    
and/or EHS      absent 1 5  
          present 14 40 1.000
(Fisher’s exact test)
BCLC classification    
 A 0 1
 B 1 0
 C 12 38  
 D 2 4  
 unknown 0 2 0.988
(Mann–Whitney U test)
ECOG PS    
 0 2 9  
 1 8 31  
 2 2 3  
 3 2 0  
 unknown 1 2 0.099
(Mann–Whitney U test)
Child-Pugh    
 A 1 13  
 B 11 13  
 C 0 4  
 unkown 3 15 0.195
(Mann–Whitney U test)
Ascites    
 absent 5 18  
 present 6 13  
 unknown 4 14 0.504
(Fisher’s exact test)
Baseline AFP (ng/ml)    
 ≤20 2 20  
 >20 11 25  
 unknown 2 0 0.103
(Fisher’s exact test)
mean duration    
sorafenib treatment    
 days (standard deviation) 161 (126) 149 (128) 0.764
(unpaired t test)